BioLife Solutions, Inc. (FRA:BJX1)

Market Cap	883.47M -26.6%
Revenue (ttm)	85.35M +87.5%
Net Income	-2.73M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	167.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	20.60
Previous Close	21.00
Day's Range	20.60 - 20.60
52-Week Range	17.50 - 27.20
Beta	n/a
RSI	32.78
Earnings Date	Mar 6, 2026

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 159
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BJX1

Financial Performance

In 2024, BioLife Solutions's revenue was $82.25 million, an increase of 8.44% compared to the previous year's $75.86 million. Losses were -$20.18 million, -70.32% less than in 2023.

Financial numbers in USD